Amyloid imaging in Alzheimer's disease

Current Opinion in Neurology

Volumn 20, Issue 4, 2007, Pages 398-402

  Nordberg, Agneta ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Amyloid; BF 227; FDDNP; Mild cognitive impairment; PIB; SB13

Indexed keywords

1,1 DICYANO 2 [6 (DIMETHYLAMINO) 2 NAPHTHALENYL]PROPENE F 18; 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE C 11; 2 [2 (2 DIMETHYLAMINOTHIAZOL 5 YL)ETHENYL] 6 [2 (FLUORO)ETHOXY]BENZOXAZOLE; 4 N METHYLAMINO 4' HYDROXYSTILBENE C 11; AMYLOID; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; FOLLOW UP; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; IN VIVO STUDY; POSITRON EMISSION TOMOGRAPHY; REVIEW;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; BENZOTHIAZOLES; BENZOXAZOLES; BRAIN; CARBON RADIOISOTOPES; FLUORINE RADIOISOTOPES; HUMANS; LONGITUDINAL STUDIES; MICE; MICE, TRANSGENIC; MOLECULAR STRUCTURE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 34447326955     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e3281a47744     Document Type: Review

References (43)

1. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18:351-357.
2. Thal DR, Rub U, Orantoes M, Braak H. Phases of A-beta deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58:1791-1800.
3. Hardy JA, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297:353-356.
4. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-791.
5. Wu C, Pike VW, Wang Y. Amyloid imaging: from benchtop to bedside. Curr Topics Dev Biol 2005; 70:171-212.
6. Friedland RP, Majocha RE, Reno JM, et al. Development of an anti-A-beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Azlheimer's disease. Mol Neurobiol 1994; 9:107-113.
7. Poduslo JF, Wengenack TM, Curran GL, et al. Molecular targeting Azheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 2002; 11:315-329.
8. Whadghiri YZ, Sigurdsson EM, Sadowski M, et al. Detections of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 2003; 50:293-302.
9. Zhang J, Yarowsky P, Gordon MN, et al. Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magn Reson Med 2004; 51:452-457.
10. Higuchi M, Iwata N, Matsuba Y, et al. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci 2005; 8:527-533.
11. Jack CR, Malgorzata M, Wengenack TM, et al. Magnetic imaging of Alzheimer pathology in the brain of living transgenic mice: a new tool in Alzheimer's disease research. The Neurosicentist 2006; 13:38-48.
12. Klunk WE, Debnath ML, Pettegrew JW. Development of small molecule probes for the betaamyloid protein of Alzheimer's disease. Neurobiol Aging 1994; 15:691-698.
13. Klunk WE, Engler H, Nordberg A, et al. Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimag Clin N Am 2003; 13:781-789.
14. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 2004; 3:519-527.
15. Klunk WE, Wang Y, Huang GF, et al. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001; 69:1471-1484.
16. Klunk WE, Wang Y, Huang GF, et al. The binding of 2-(4′-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 2003; 23:2086-2092.
17. Klunk W, Lopresti BJ, Ikonomovic MD, et al. Binding of positron emission tomography tracer Pittsburgh Compound-B reflects the amount of amyloid-β in Alzheimer's disease brain but not in transgenic mice brain. J Neurosci 2005; 25:10598-10606.
18. Shoghi-Jadid K, Small D, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brain of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002; 10:24-35.
19. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004; 55:306-319.
20. Verhoeff NP, Wilson AA, Takeshita S, et al. In vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am Geriatr Psychiatry 2004; 12:584-595.
21. Kudo Y, Okamura N, Forumoto S, et al. 2-(2-[2- Dimethylaminothiazol-5-yl] ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 2007; 49:554-561.
22. Agdeppa ED, Kepe V, Liu J, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphtylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer's disease. J Neurosci 2001; 21:1-5.
23. Agdeppa ED, Kepe V, Liu J, et al. Dialkylamino-6- acylmalonnonitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tool in Alzheimer's disease. Mol Imaging Biol 2003; 5:404-417.
24. Ye L, Morgenstern JL, Gee AD, et al. Delineation of PET imaging agent binding sites on beta-amyloid peptide fibrils. J Biol Chem 2005; 280:23599-23604.
25. Bresjanac M, Smid LM, Vovko TD, et al. Molecular-imaging probe-2-(1-[6-[(fluoroethyl)(methyl)amino-2-naphthyl]ethylidene)malonitrile labels prion plaques in vitro. J Neurosci 2003; 23:8029-8033.
26. Kung M-P, Hou C, Zhuang Z-P, et al. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissue of patients with Alzheimer's disease. Brain Res 2004; 1025:98-105.
27. Lochart A, Ye L, Judt DB, et al. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem 2005; 280:7677-7684.
28. Bacskai BJ, Hickey GA, Skoch J, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice. Proc Natl Acad Sci U S A 2003; 100:12462-12467.
29. van Groen T, Kiliaan AJ, Kadish I. Deposition of mouse amyloid beta in human APP/PS double and single AD mouse transgenic mice. Neurobiol Dis 2006; 23:653-662.
30. Bergstrom M, Grahnen A, Långström B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003; 59:357-366.
31. Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modelling of amyloid binding in humans using PET imaging and Pittsburgh compound-B. J Cerebral Blood Flow Metab 2005; 25:1528-1547.
32. Archer HA, Edison P, Brooks DJ, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006; 60:145-147.
33. Engler H, Forsberg A, Almkvist O, et al. Two year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129:2856-2866. Alzheimer's disease patients show stable PIB retention despite progress in cerebral glucose metabolism and cognition.
34. Kemppainen NM, Aalto S, Wilson IA, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 2006; 67:1575-1580.
35. Mintun MA, LaRosso GN, Dence CS, et al. (11C)PIB in a nondemented population: potentional antecendent marker of Alzheimer's disease. Neurology 2006; 67:446-452. PIB imaging is observed in healthy controls.
36. Ziolko SK, Weissfeld LA, Klunk WE, et al. Evaluation of voxel-based methods for the statisitical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. NeuroImage 2006; 33:94-102.
37. Edison P, Archer HA, Hinz A, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007; 68:501-508.
38. Small G, Kepe V, Ercoli LM, et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006; 355:2652-2663. 18F-FDDNP showed higher binding in MCI and Alzheimer's disease patients compared with controls.
39. Lopresti BJ, Klunk WE, Matthis CA, et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative study. J Nucl Med 2005; 46:1959-1972.
40. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (in press).
41. Batesman RJ, Munsell LY, Morris JC, et al. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006; 12:856-861. First study of measurement of production and clearance of Aβ as measured in cerebrospinal fluid.
42. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol 2006; 59:512-519. A negative correlation was observed between brain PIB retention and cerebrospinal fluid amyloid 1-42 in Alzheimer's disease patients.
43. Klunk WE, Mathis CE, Price JC, et al. Two year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129:2805-2807.